Abstract CT322: Efficacy of first-line capecitabine (CAP) ± bevacizumab (BEV) according to risk factors in the RIBBON-1 randomized phase III trial in locally recurrent/metastatic breast cancer (LR/mBC)
Keyword(s):
2011 ◽
Keyword(s):
2013 ◽
Keyword(s):
Keyword(s):
Keyword(s):
2005 ◽
Vol 3
(2)
◽
pp. 77-78
◽
Keyword(s):
2006 ◽
Vol 94
(9)
◽
pp. 1233-1236
◽
Keyword(s):
Keyword(s):
Keyword(s):